Announces Research Collaboration, Option And License Agreement With Alexion To Develop A Therapy Using J-Brain Cargo For Neurodegenerative Disease
30/03/2023 08:03
March 30 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T :
* ANNOUNCES RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT WITH
ALEXION TO
DEVELOP A THERAPY USING J-BRAIN CARGO FOR NEURODEGENERATIVE DISEASE
Source text for Eikon: ID:nTSod83ccf
Further company coverage: 4552.T
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results